Vyome Holdings, Inc. · NASDAQ:HIND
Vyome — Technical Presentation (February 2026)
15 slides from Vyome's technical presentation, Feb 13, 2026
Slide 1: VT-1953 in Treating Symptoms of Malignant Fungating Wounds: Phase 2 IST Study Results & Next Steps
VT - 1953 in Treating Symptoms of Malignant Fungating Wounds (MFW) PHASE 2 IST STUDY RESULTS & NEXT STEPS © Vyome Holdings, Inc. February 2026
Slide 2: Forward-looking statements
VYOME HOLDINGS, INC. (“Vyome”) 2 Any statements contained in this presentation that do not describe historical facts may constitute forward - looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 . These statements may be identified by words such as “beli
Slide 3: Key Takeaways From Phase 2 Study
Key Takeaways From Phase 2 Study Clear efficacy and safety signals to support further clinical development . VT - 1953 achieved a significant improvement (P=0.002) in the primary endpoint of malodor on Day 14 vs baseline as scored by investigators. The improvement seen with VT - 1953 was statistical
Slide 4: What is MFW?
MFW is a rare condition seen in ~10% of advanced cancer patients.* Patients suffer from distressing symptoms, including: Malodor (like “rotten meat”**) What is MFW? *The Microbiome, Malignant Fungating Wounds, and Palliative Care. Front. Cell. Infect. Microbial., November 2019, EASED study (2023). *
Slide 5: Study design and patient demographics
Active arm (VT - 1953 b.i.d): 10 patients Sex: 7 male, 3 female. Age: median 50.5, mean 56, range 37 – 77) Diagnosis counts: Oral/Head and Neck cancer: 7; Breast cancer : 2; Vulval cancer: 1 Vehicle arm (5 patients) Sex: 3 male, 2 female. Age: median 47, mean 45.8, range 31 – 61) Diagnosis counts: O
Slide 6: VT-1953 significantly reduced malodor: primary endpoint
VT - 1953 treatment significantly reduced malodor (scored by investigator on Day 14): primary endpoint debt Treatment with VT - 1953 2% topical Gel resulted in a statistically significant improvement in malodor symptom by Day 14 (p = 0.0020, vs baseline. Wilcoxon Signed - Rank Test), while no signif
Slide 7: VT-1953 reduces impact of malodor on quality of life: secondary endpoint
VT - 1953 reduces the negative impact of malodor on quality of life (patient reported): secondary endpoint Scored on 5 components: Awareness of malodor Concern about malodor noticed by others Reluctance to socialize because of odor Nauseated by the odor Odor affects appetite 5 YES 0 YES 0 (worst) 5
Slide 8: VT-1953 significantly reduced malodor scored by patients on VAS
VT - 1953 significantly reduced malodor (scored by patients on VAS Scale): exploratory endpoint Patients scored a reduction in malodor with VT - 1953, median scores decreasing to 2.5 (Q1: 2.0, Q3: 3.0) by Day 14 from a baseline median malodor score of 7.5 (Q1: 7.0, Q3: 9.0) (p = 0.0020, Wilcoxon Sig
Slide 9: VT-1953 significantly reduced lesion pain
VT - 1953 significantly reduced lesion pain (scored by patients on VAS Scale): exploratory endpoint Patients treated with VT - 1953 reported a statistically significant decrease in pain intensity by Day 14 to median score of 4.0 (Q1: 3.0, Q3: 4.0) from a baseline median score of 6 (Q1: 5.0, Q3: 7.0)
Slide 10: VT-1953 did not significantly reduce exudate
VT - 1953 did not significantly reduce exudate: exploratory endpoint At Day 14, the overall median exudate amount remained unchanged compared to baseline A statistically significant difference was observed between treatment groups at Day 14 (p = 0.0268), favoring the VT - 1953 Topical Gel group. Wit
Slide 11: VT-1953 significantly improves QoL
VT - 1953 significantly improves QoL (patient - reported outcome measures): exploratory endpoint Severe difficulty 11 No difficulty Mean of all individual QoL components was computed by visit for each subject, and the median analysis was then performed on these mean composite scores. Patient - repor
Slide 12: VT-1953 did not exhibit any safety signals
VT - 1953 did not exhibit any safety signals during the study period at doses used • No TEAEs reported • No changes in vital signs • No reports of local skin reactions • *Consistent with observations from prior clinical trials with VT - 1953 12 * VT - 1953 (2% topical gel) has been studied for safet
Slide 13: Summary
Treatment with VT - 1953 for 14 days successfully met its primary endpoint of significantly reducing malodor associated with MFW as scored by investigators. There is consistency between investigator scores (on TELER score) and malodor scored by patients using VAS (exploratory endpoint) Summary Patie
Slide 14: Anticipated Milestones – Key Focus of Vyome
VT - 1953 Anticipated Milestones – Key Focus of Vyome The orphan drug designation application for VT - 1953 has been filed and discussions regarding CRO estimates ongoing Orphan drug designation approval Discussions with FDA on Phase 3 design Finalize CRO contracts First patient in Phase 3 trial Pha
Slide 15: Vyome Holdings, Inc. contact
Vyome Holdings, Inc. (“Vyome”) Venkat Nelabhotla, CEO & Co - Founder nvenkat@vyometx.com +1 (973) 832 - 8147 Suite 400, One Mifflin Place, Harvard Square Cambridge, MA 02138
Vyome Holdings — Technical Presentation (February 2026) on 6ix